Antimicrobial susceptibility data of plasmid-mediated AmpC beta-lactamase- and ESBL-producing Enterobacteriaceae (each 39 patients).

<p>Abbreviations: pAmpC, plasmidic AmpC beta-lactamase; ESBL, Extended-Spectrum beta-Lactamase; n.a., not available; CLSI, Clinical and Laboratory Standards Institute</p><p>Percentages were calculated using susceptible isolates as nominator and all tested isolates as denominator, which was different for each antibiotic</p><p>* pAmpC producers normally are susceptible to cefepime. In five patients additional ESBL-production was documented partially explaining resistance</p><p>‡ Not available in accordance with the CLSI recommendations during the study period to report ESBL always as non-susceptible to cephalosporins</p><p>§ Susceptibility pattern of the VITEK did not include fosfomycin during the study period, therefore only a part of the isolates was tested (mostly on request by the treating physician)</p><p>Antimicrobial susceptibility data of plasmid-mediated AmpC beta-lactamase- and ESBL-producing Enterobacteriaceae (each 39 patients).